1. bookVolume 62 (2012): Edition 3 (September 2012)
Détails du magazine
License
Format
Magazine
eISSN
1846-9558
ISSN
1330-0075
Première parution
28 Feb 2007
Périodicité
4 fois par an
Langues
Anglais
Accès libre

Colon specific delivery of budesonide based on triple coated pellets: in vitro/in vivo evaluation

Publié en ligne: 06 Nov 2012
Volume & Edition: Volume 62 (2012) - Edition 3 (September 2012)
Pages: 341 - 356
Détails du magazine
License
Format
Magazine
eISSN
1846-9558
ISSN
1330-0075
Première parution
28 Feb 2007
Périodicité
4 fois par an
Langues
Anglais

1. D. C. Baumgart, Treatment of inflammatory bowel disease: A review of medical therapy, World J. Gastroenterol. 21 (2008) 354-377; DOI: 10.3748/wjg.14.354.10.3748/wjg.14.354Search in Google Scholar

2. U. Klotz and M. Schwab, Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease, Adv. Drug Deliv. Rev. 57 (2005) 267-279; DOI: 10.1016/j.addr.2006.09.011.10.1016/j.addr.2006.09.011Search in Google Scholar

3. M. Jiménez and A. S. Peña, Budesonide for ulcerative colitis, Rev. Esp. Enferm. Dig. 98 (2006) 362-373; DOI: 1130-0108/2006/98/5/362-373.Search in Google Scholar

4. K. Dilger, M. Alberer, A. Busch, A. Enninger, R. Behrens, S. Koletzko, M. Stern, C. Beckmann and C. H. Gleiter, Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn’s disease, Aliment. Pharmacol. Ther. 23 (2006) 387-395; DOI: 10.1111/j.1365-2036.2006. 02771.x.Search in Google Scholar

5. J. Seidegård, L. Nyberg and O. Borgå, Presystemic elimination of budesonide in man when administered locally at different levels in the gut, with and without local inhibition by ketoconazole, Eur. J. Pharm. Sci. 15 (2008) 264-70; DOI: 10.1016/j.ejps.2008.07.005.10.1016/j.ejps.2008.07.005Search in Google Scholar

6. L. F. Asghar and S. Chandran, Multiparticulate formulation approach to colon specific drug delivery: current perspectives, J. Pharm. Pharm. Sci. 9 (2006) 327-338.Search in Google Scholar

7. Y. Krishnamachari, P. Madan and S. Lin, Development of pH- and time-dependent oral microparticles to optimize budesonide delivery to ileum and colon, Int. J. Pharm. 29 (2007) 238-47; DOI: 10.1016/j.ijpharm.2007.02.015.10.1016/j.ijpharm.2007.02.015Search in Google Scholar

8. A. Makhlof, Y. Tozuka and H. Takeuchi, pH-Sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model, Eur. J. Pharm. Biopharm. 72 (2009) 1-8; DOI: 10.1016/j.ejpb.2008.12.013.10.1016/j.ejpb.2008.12.013Search in Google Scholar

9. United States Pharmacopoeia 32, National Formulary 29, USP Convention, Rockville 2002.Search in Google Scholar

10. J. Varshosaz, J. Emami, N. Tavakoli, A. Fassihi, M. Minaiyan, F. Ahmadi and F. Dorkoosh, Synthesis and evaluation of dextran-budesonide conjugates as colon specific prodrugs for treatment of ulcerative colitis, Int. J. Pharm. 365 (2009) 69-76; DOI: 10.1016/j.ijpharm.2008.08.034.10.1016/j.ijpharm.2008.08.034Search in Google Scholar

11. J. Ding, X. Wang, T. Zhang, Q. Li and M. Luo, Optimization of RP-HPLC analysis of low molecular weight organic acids in soil, J. Liq. Chrom. Rel. Tech. 29 (2006) 99-111; DOI: 10.1080/10826070500363050.10.1080/10826070500363050Search in Google Scholar

12. T. Higuchi, Mechanism of sustained-action medication, J. Pharm. Sci. 52 (1963) 1145-1149; DOI: 10.1002/jps. 2600521210.Search in Google Scholar

13. R. W. Korsmeyer, R. Gurny, E. Doelker, P. Buri and N. A. Peppas, Mechanisms of solute release from porous hydrophilic polymers, Int. J. Pharm. 15 (1983) 25-35; DOI: 10.1016/0378-5173(83)90064-9.10.1016/0378-5173(83)90064-9Search in Google Scholar

14. N. A. Peppas, Analysis of Fickian and non-Fickian drug release from polymers, Pharm. Acta Helv. 60 (1985) 110-111.Search in Google Scholar

15. P. Costa and J. M. Sonsa Lobo, Modelling and comparison of dissolution profiles, Eur. J. Pharm. Sci. 13 (2001) 123-133; DOI: 10.1016/S0928-0987(01)00095-1.10.1016/S0928-0987(01)00095-1Search in Google Scholar

16. G. P. Morris, P. L. Beck, M. S. Herridge, W. T. Depew, M. R. Szewczuk and J. L. Wallace, Hapten-induced model of colonic inflammation and ulceration in the rat colon, Gastroenterology 96 (1989) 795-803.10.1016/0016-5085(89)90904-9Search in Google Scholar

17. S. Choudhary, A. Keshavarzian, S. Yong, M. Wade, S. Bocckino, B. J. Day and A. Banan, Novel antioxidants zolimid and AEOL11201 ameliorate colitis in rats, Dig. Dis. Sci. 46 (2001) 2222-2230; DOI: 10.1023/A: 1011975218006.Search in Google Scholar

18. S. Y. Zhou, Q. B. Mei, L. Liu, X. Guo, B. S. Qiu, D. H. Zhao and C. H. Cho, Delivery of glucocorticoid conjugates in rat gastrointestinal tract and its treatment for ulcerative colitis, Acta Pharmacol. Sin. 22 (2001) 761-764.Search in Google Scholar

19. J. L. Wallace and C. M. Keenan, An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis, Am. J. Physiol. 258 (1990) 527-534.Search in Google Scholar

20. C. B. Appleyard and J. L. Wallace, Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs, Am. J. Physiol. 269 (1995) 119-125.Search in Google Scholar

Articles recommandés par Trend MD

Planifiez votre conférence à distance avec Sciendo